Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pilot study of Escherichia coli Nissle 1917 as probiotic adjuvant in type 2 diabetes mellitus
2014-000936-40Phase 3Completed
- Sponsor
- GWT-TUD
- Start
- May 2014
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Countries
- 1
01
Overview
Phase 3 trial of escherichia coli nissle 1917 in type 2 diabetes mellitus (T2DM), sponsored by GWT-TUD. Primary endpoint: Change in HbA1c from baseline to end of treatment. Started May 2014; status: completed.
02
Drugs
escherichia coli nissle 1917
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2014-000936-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-000936-40.